Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

Krka firms up its focus on global footprint

Krka is keen to expand its geographic presence beyond its stronghold in Europe, especially by capitalising on the “huge opportunity” in China. But it has no immediate plans to build a major presence in the Americas, according to the Slovenian group’s management board member David Bratoz.

Business Strategies Sales & Earnings

US modafinil charge devastates Sun profit

Sun’s managing director, Dilip Shanghvi, has defended the “underlying health” of the company after a sizeable charge linked to antitrust litigation almost completely wiped out Sun’s pre-tax profit in its financial second quarter, while a sales decline in India limited overall turnover growth.

Sales & Earnings

Nichi-Iko aids Elmed under deal with Eisai

Nichi-Iko has started promoting the value-added portfolio of Eisai’s Elmed in Japan under a strategic alliance struck earlier this year that also includes Nichi-Iko acquiring all shares in Elmed by 1 April 2019. As part of the “phased acquisition” (Generics bulletin, 6 April 2018, page 3), Nichi-Iko said it had by 1 October acquired a third of stocks in Elmed for a total of ¥5.47 billion (US$48.7 million).

Business Strategies Sales & Earnings

Launches help Towa exceed its profit goal

Significant sales increases for products launched in its previous financial year helped Towa to register turnover up by a tenth to ¥49.1 billion (US$435 million) in its financial first half ended 30 September 2018. Products launched in 2017 – including telmisartan, miglitol and orodispersible olmesartan – accounted for ¥3.6 billion of first-half sales, up from ¥1.2 billion in the first half in 2017. Meanwhile, more recent launches from 2018, such as lamotrigine and minodronic acid, generated sales of ¥0.8 billion.

Sales & Earnings

Rovi rolls out Becat enoxaparin in Europe

Introducing its Enoxaparin Becat biosimilar in both Spain and France during September this year – in the latter market through partner Biogaran – enabled Laboratorios Farmacéuticos Rovi to report turnover from the low molecular weight heparin (LMWH) of €7.8 million (US$8.9 million) in the third quarter, and €16.7 million in the first nine months, of this year. The Spanish firm has also just rolled out Becat in Austria and Latvia.

Business Strategies Sales & Earnings

Concordia in clear on three products in UK

Concordia International no longer faces a UK probe into “alleged anti-competitive agreements and/or concerted practices” for three of the firm’s products – trazodone, nefopam and dicycloverine – after the country’s Competition and Markets Authority (CMA) closed an investigation on “administrative priority grounds”.

Business Strategies Sales & Earnings
See All
UsernamePublicRestriction

Register